FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2982449816> ?p ?o ?g. }

• W2982449816 endingPage "160" @default.
• W2982449816 startingPage "151" @default.
• W2982449816 abstract "Introduction: Gadolinium-based contrast agents are widely used for magnetic resonance imaging and, until recently, had been generally considered to have an excellent safety profile in patients with normal renal function. Nephrogenic systemic fibrosis is a well-established disease process involving fibrosis of the skin and internal organs seen in some patients with severely impaired renal function following exposure to these agents. Following reports that individuals with normal renal function may experience gadolinium deposition within brain and bone tissue, the term “gadolinium deposition disease” has been proposed and the use of chelating agents has been recommended to treat this “disease”.Objectives: This review will address the clinical evidence for “gadolinium deposition disease” and discuss whether chelation therapy is appropriate for individuals who believe they have this condition.Methods: Electronic databases (PUBMED, Ovid MEDLINE and EMBASE) were searched up to 1st October 2019 for all studies evaluating clinical signs or symptoms related to potential gadolinium toxicity post-gadolinium-based contrast agent exposure in subjects with normal renal function, or papers evaluating the potential chelation of gadolinium in humans.Does “gadolinium deposition disease” exist as a novel condition? We identified four clinical studies relating to “gadolinium deposition disease”, including one that included some discussion of the use of chelation therapy. Two of the clinical studies presented data from anonymous online surveys that recruited participants from support forums for people who self-identified as having gadolinium-based contrast agent–induced toxicity, with questions focussing on their reported symptoms and signs. The published literature to date has demonstrated that gadolinium deposition within the brain primarily occurs within the dentate nucleus and globus pallidus. These patients did not complain of movement disorders, but instead reported generalised sensory symptoms, which would not be expected to occur with pathology in these areas of the brain. There was considerable selection bias and a lack of available clinical information to exclude alternative medical diagnoses for these series, thus rendering the results difficult to interpret.Role of chelation therapy in patients exposed to gadolinium-based contrast agent: One study reported data from 25 patients who were diagnosed with “gadolinium deposition disease” according to unspecified criteria and were treated with intravenous calcium or zinc trisodium pentetate. The authors reported an increase in urine gadolinium concentrations following administration of the chelating agents, which they attributed to re-chelation of gadolinium from tissue deposits, however, there are insufficient data to be able to substantiate this.Conclusion: There is currently no published information from well-designed clinical studies that support a link between gadolinium deposition and the development of clinical sequelae in patients with normal renal function. Clinicians should exercise caution when considering whether or not gadolinium is of relevance in patients reporting symptoms after administration of gadolinium-based contrast agents. The inappropriate use of chelation therapy in patients with no clear evidence-based indication for their use potentially increases the risk of clinically significant harm to these patients from the adverse effects of chelation. Further research and well-designed clinical and epidemiological surveillance is needed to determine whether there are toxicological risks related to gadolinium exposure from the use of gadolinium-based contrast agents in patients with normal renal function." @default.
• W2982449816 created "2019-11-08" @default.
• W2982449816 creator A5015960673 @default.
• W2982449816 creator A5087658580 @default.
• W2982449816 date "2019-10-30" @default.
• W2982449816 modified "2023-10-02" @default.
• W2982449816 title "Gadolinium-based contrast agents – what is the evidence for ‘gadolinium deposition disease’ and the use of chelation therapy?" @default.
• W2982449816 cites W155004123 @default.
• W2982449816 cites W1806101983 @default.
• W2982449816 cites W1940024491 @default.
• W2982449816 cites W1965758010 @default.
• W2982449816 cites W1965786357 @default.
• W2982449816 cites W1973118105 @default.
• W2982449816 cites W1986391726 @default.
• W2982449816 cites W2005943740 @default.
• W2982449816 cites W2017673907 @default.
• W2982449816 cites W2032095902 @default.
• W2982449816 cites W2032796538 @default.
• W2982449816 cites W2035396874 @default.
• W2982449816 cites W2049134111 @default.
• W2982449816 cites W2049382856 @default.
• W2982449816 cites W2058914126 @default.
• W2982449816 cites W2059283030 @default.
• W2982449816 cites W2060437861 @default.
• W2982449816 cites W2062162151 @default.
• W2982449816 cites W2066801370 @default.
• W2982449816 cites W2066876596 @default.
• W2982449816 cites W2071712292 @default.
• W2982449816 cites W2087404899 @default.
• W2982449816 cites W2100095818 @default.
• W2982449816 cites W2104719948 @default.
• W2982449816 cites W2108452679 @default.
• W2982449816 cites W2110638082 @default.
• W2982449816 cites W2125409822 @default.
• W2982449816 cites W2129768655 @default.
• W2982449816 cites W2133231258 @default.
• W2982449816 cites W2140036864 @default.
• W2982449816 cites W2155961553 @default.
• W2982449816 cites W2169262628 @default.
• W2982449816 cites W2268080112 @default.
• W2982449816 cites W2312938814 @default.
• W2982449816 cites W2315022551 @default.
• W2982449816 cites W2401957300 @default.
• W2982449816 cites W2402599287 @default.
• W2982449816 cites W2407825305 @default.
• W2982449816 cites W2414174338 @default.
• W2982449816 cites W2415476931 @default.
• W2982449816 cites W2507120718 @default.
• W2982449816 cites W2515055839 @default.
• W2982449816 cites W2518169464 @default.
• W2982449816 cites W2535717906 @default.
• W2982449816 cites W2560467450 @default.
• W2982449816 cites W2590902585 @default.
• W2982449816 cites W2595375099 @default.
• W2982449816 cites W2599004004 @default.
• W2982449816 cites W2606869745 @default.
• W2982449816 cites W2617252489 @default.
• W2982449816 cites W2626613451 @default.
• W2982449816 cites W2695045525 @default.
• W2982449816 cites W2791006626 @default.
• W2982449816 cites W2791769218 @default.
• W2982449816 cites W2802969230 @default.
• W2982449816 cites W2803383982 @default.
• W2982449816 cites W2884335025 @default.
• W2982449816 cites W2895630837 @default.
• W2982449816 cites W2895854599 @default.
• W2982449816 cites W2898102107 @default.
• W2982449816 cites W2902544181 @default.
• W2982449816 cites W4232488520 @default.
• W2982449816 cites W4250940682 @default.
• W2982449816 cites W4255225325 @default.
• W2982449816 cites W796214945 @default.
• W2982449816 doi "https://doi.org/10.1080/15563650.2019.1681442" @default.
• W2982449816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31663374" @default.
• W2982449816 hasPublicationYear "2019" @default.
• W2982449816 type Work @default.
• W2982449816 sameAs 2982449816 @default.
• W2982449816 citedByCount "29" @default.
• W2982449816 countsByYear W29824498162020 @default.
• W2982449816 countsByYear W29824498162021 @default.
• W2982449816 countsByYear W29824498162022 @default.
• W2982449816 countsByYear W29824498162023 @default.
• W2982449816 crossrefType "journal-article" @default.
• W2982449816 hasAuthorship W2982449816A5015960673 @default.
• W2982449816 hasAuthorship W2982449816A5087658580 @default.
• W2982449816 hasConcept C126838900 @default.
• W2982449816 hasConcept C142724271 @default.
• W2982449816 hasConcept C143409427 @default.
• W2982449816 hasConcept C178790620 @default.
• W2982449816 hasConcept C185592680 @default.
• W2982449816 hasConcept C204787440 @default.
• W2982449816 hasConcept C2777218474 @default.
• W2982449816 hasConcept C2779134260 @default.
• W2982449816 hasConcept C2781027423 @default.
• W2982449816 hasConcept C557651011 @default.
• W2982449816 hasConcept C71924100 @default.
• W2982449816 hasConceptScore W2982449816C126838900 @default.
• W2982449816 hasConceptScore W2982449816C142724271 @default.

• next